Lipoprotein(a) Linked to Increased Cardiovascular Risk Even With Standard Treatment

Lipoprotein(a) (Lp[a]) remains an independent risk factor for atherosclerotic cardiovascular disease (CVD) and calcific valvular aortic stenosis, even in individuals receiving standard treatments, according to recent reporting from Medical Xpress.

Lp(a) is a low-density lipoprotein–like molecule with an apolipoprotein (b) moiety covalently attached to apolipoprotein (a) (Apo[a]), a plasminogen-like protein that confers atherogenic, thrombogenic, and proinflammatory properties. It is produced mainly in the liver and reaches adult levels in childhood, typically by age 5, with little subsequent change except during periods of significant inflammation, liver disease, or kidney disease.

Lp(a) levels are genetically determined and show minimal influence from environmental or lifestyle factors. An estimated 20-25% of the global population has elevated Lp(a) levels, which are highest among persons of African ancestry due to race/ethnic variations.

Current guidelines support once-in-a-lifetime measurement of Lp(a) in most individuals with increased risk of atherosclerotic CVD. However, because Lp(a) does not respond significantly to lifestyle modifications or standard lipid-lowering therapies such as statins, elevated levels persist despite otherwise guideline-recommended LDL-C control and treatment adherence.

Emerging data indicate a strong correlation between high Lp(a) levels and elevated high-sensitivity C-reactive protein (hs-CRP) levels, suggesting a combined role in predicting CVD risk. This association underscores the inflammatory dimension of Lp(a)-related pathology beyond its atherogenic and thrombogenic effects.

New therapeutic approaches are under development that target the LPA gene to reduce Lp(a) production at the translational level. These emerging therapies aim to address a gap in current treatment options, as no approved drugs specifically lower Lp(a) are widely available for routine clinical use.

While Lp(a) is thought to have a role in wound healing, many individuals have undetectable levels, raising questions about its physiological necessity. Nonetheless, its presence at elevated levels is causally linked to increased risk of atherosclerotic cardiovascular disease and aortic valve stenosis, independent of traditional risk factors.